小儿疳证源流考

疳作为一个病名，最早见于隋《诸病源候论》。首先将疳证作为儿科专有疾病者，为宋初《太平圣惠方》。本病分类最全面，收集方剂最丰富当推宋《幼幼新书》。南宋出版的《小儿卫生总微论方》首次将疳证归类为五疳。本草文献中对本病贡献最大的为明《本草纲目》。清《温病条辨》首次将本病治法作全面总结。１９９４年国家中医药管理局颁布的《中医病证诊断疗效标准》首次以法规的形式将本病作了统一规范     

Factors impacting on quality of life in Parkinson's disease: Results from an international survey

Current management guidelines for the treatment of patients with Parkinson's disease (PD) are limited due to the lack of knowledge of factors that influence health‐related quality of life (HRQL). To assess the HRQL of people with PD, and to systematically identify and evaluate those factors (other than disease severity and medication, which could have an impact), we undertook a cross‐sectional, randomized selection, multicenter international survey of patients with PD, caregivers, and clinicians. Face‐to‐face interviews were conducted with subjects in six countries. Disease severity, medication, and other factors hypothesized to influence HRQL were assessed using a combination of specially developed questionnaires and validated instruments including the Parkinson's Disease Questionnaire‐39 (HRQL), Hoehn and Yahr Stage (disease severity), and Beck's Depression Inventory (BDI; depression). Multiple linear regression models were used to demonstrate whether the factors investigated contribute significantly to HRQL. The results obtained indicated that Hoehn and Yahr stage and medication explained only 17.3% of the variability in HRQL of patients with PD, although both were significant (R² = 0.173, P < 0.05). Other factors increased the explanatory power to adjusted R² = 0.597, with BDI being the most significant predictor of variability in HRQL (adjusted R² = 0.582; P < 0.001), followed by “Satisfaction with the explanation of the condition at diagnosis” and “Current feelings of optimism” (both P < 0.05). These factors, in addition to disease severity and medication, explain 59.7% of the variability in HRQL across the population. In conclusion, depression (as measured by the BDI) in PD, “satisfaction with the explanation of the condition at diagnosis” and “current feelings of optimism” have a significant impact on HRQL. The completion of this initial analysis is the first step towards developing management guidelines that truly influence the HRQL of patients with PD. © 2001 Movement Disorder Society.     

黄芪注射液治疗心力衰竭46例临床观察

目的　探讨黄芪注射液对心力衰竭 (HF)的治疗效果。方法　选择 92例住院HF患者随机分为治疗组和对照组 ,对照组给予常规治疗 ,治疗组在常规治疗的基础上给予黄芪注射液 30ml加 5 %葡萄糖液 2 5 0ml,静滴 ,每日一次 ,共 2周。疗程结束后 ,观察心功能改善情况。结果　治疗组有效率 93.4 8% ,对照组有效率 71.74 % ,两组对比 ,差异显著 (P <0 .0 1)。结论　黄芪注射液对HF的治疗效果佳 ,副作用少 ,值得推广。     

血管紧张素转换酶基因多态性与冠心病关系的研究

目的：探讨血管紧张素转换酶（ACE）基因多态性与冠心病及冠状动脉病变支数的关系。方法：应用PCR扩增ACE基因的16内含子上的287bp插入／缺失片段，确定ACE基因型。在各组间进行基因型和等位基因频率的比较，采用多因素逐步logistic回归分析ACE的DD基因型及其他易患因素对冠心病的作用。用冠状动脉造影标准确诊冠心病。结果：（1）冠心病组ACE的DD基因型和D等位基因频率均高于对照组（x^2分别为16．04，16．08；P均＜0．01）。D等位基因与冠心病的关联性较高（隐性作用时OR＝2．15，P＜0．01，显性作用时OR＝2．84，P＜0．01）。（2）冠状动脉单支，双支，三支病变组之间，ACE基因型分布和D等位基因频率均一致（x^2分别为1．50，1．06，P均＞0．05）。（3）多因素逐步logistic回归分析，排除公认的冠心病危险因素后，ACE的DD基因型仍是冠心病的危险因素。结论：（1）ACE基因多态性与冠心病有相关性；（2）ACE基因型分布和D等位基因频率与冠状动脉病变支数无关；（3）ACE的DD基因型是冠心病的独立危险因素。     

超微孔膨体聚四氟乙烯人工心脏瓣膜体外流体力学的评价

目的采用新型高分子材料制备人工心脏瓣膜,并对其体外流体力学特征作出评价。方法将片状超微孔膨体聚四氟乙烯材料缝制于弹性支架上做成人工心脏瓣膜,以Baxter人工双叶机械瓣作对照,对新型瓣膜进行了静态泄漏和定常流测试。结果两种瓣膜静态泄漏率无显著差异(P>0.05),定常流下高分子瓣膜跨瓣压差更低,两组间存在显著差异(P<0.001)。结论新型高分子人工心脏瓣膜体外流体动力学性能优于Baxter机械瓣。     

豚鼠离体心脏心电场分布的研究

目的确定豚鼠心电场的分布本质。方法将26只离体豚鼠心脏浸入蒸馏水和生理盐水中,将参比点置于远离心电场源的零电位,记录3个平面左、右心室侧和与之垂直的前后侧共4个方向上不同距离的心电图。结果每一平面4个方向上共16个点在两种溶液中都记录到以正波为主的心电图。结论排除导联参比点对体表标测的影响,心电场一致向外的分布方式表明心电场不是偶极场,可能是一个拟球面分布的单源场。     

无心肌梗死冠心病患者心功能变化与室性心律失常的关系

目的：探讨冠心病心力衰竭对各种室性心律失常的影响。方法：选择381例冠心病住院患者，根据心功能分级标准（NYHA）分为4组，检测24h动态心电图（Holter），分析室性心律失常类型及发生率，进行统计分析。结果：各级心功能组其室性心律失常发生率经x^2检验示，室性心律失常的发生率除联律和持续性或非持续性室性心动过速外各组间差异无显著性（P＞0．05）。结论：非心肌梗死冠心病患者室性心律失常发作频率与心力衰竭的程度无关，但联律和持续或非持续性室性心动过速在重度心力衰竭患者发生率增加。     

心脏移植术后急性排异反应的监测

目的 总结原位心脏移植术后急性排异反应的监测。方法 2000－01／2002－04施行11例原位心脏移植手术，结合临床表现、心电图、超声心动图、化验检查及心内膜活栓等检查，对心脏移植术后急性排异反应的监测进行分析。结果 采用临床症状＋心电图＋超声心电图＋心肌血清学检测综合判断有6次急性排异反应，行心内膜活检证实Ⅰb级2次，Ⅲa级3次；术后常规行心内膜活检21次，仅发现急性排异反应Ⅰa或Ⅰb级5次。结论 急性排异反应是关系到心脏移植术后患者康复及愈后的重要因素，因此要及时、有效地进行监测；心内膜心肌活检是诊断急性排异反应敏感可靠的方法，但为有创性检查，有一定的并发症风险，其他多项无创性检查可作辅助指标，因此急性排异反应监测应把无创性检查与心内膜心肌活检有机地结合起来。     

经皮冠状动脉腔内支架置入术治疗冠心病

目的:评估冠状动脉内支架置入术的效果。方法:回顾性分析1996年2月～2000年2月我院接受冠状动脉内支架置入术的120例病人的治疗效果。结果:在183处病变共置入支架125只。在未经介入性治疗的病变置入支架(De novo stenting)101只,PTCA结果不理想(suboptimal)置入支架19只,2例PTCA并发夹层,濒临闭塞时紧急置入支架(Bail-out stenting)2只,在再狭窄病变置入支架3只。置入支架平均直径3.00±0.69mm,平均长度18.15±10.26mm。手术即刻成功率98.4％,主要并发症率为1.6％((2例AMI)。结论:冠脉内支架置入术是治疗冠心病的一种安全有效的介入性治疗技术,其成功率高,并发症少。     

Comparison of Sputum and Serum Eosinophil Cationic Protein (ECP) Levels in Nonatopic Asthma and Chronic Obstructive Pulmonary Disease

The aim of the present study was to investigate whether sputum eosinophil cationic protein (ECP) concentrations could be a useful marker in the differential diagnosis between intrinsic asthma and chronic obstructive pulmonary disease (COPD). For this purpose total blood eosinophil counts were obtained and concentrations of serum and sputum ECP from 10 nonatopic asthmatics with a mild attack and 9 COPD patients with acute exacerbation were measured by radioimmunoassay. Mean serum ECP concentration was 54.3 ± 23.0 g/L in the asthmatic group and 83.3 ± 79.2 g/L in the COPD group (p: n.s.). In the group of asthmatics mean sputum ECP level was 984.5 ± 1245.5 mg/L/g sputum and in the COPD group it was 417.5 ± 363.5 mg/L/g sputum. There was no significant difference in sputum ECP levels between patients with asthma and COPD. We conclude that neither sputum nor serum ECP levels are useful markers in differential diagnosis of asthma attack and acute exacerbation of COPD.